Trial Profile
A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of AL-108 After 12 Weeks of Intranasal Administration in Subjects With Mild Cognitive Impairment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Davunetide (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- Sponsors Allon Therapeutics
- 31 Jul 2008 Primary endpoint results presented at ADRD in July 2008
- 28 Jul 2008 Allon Therapeutics to present AL-108 phase IIa efficacy data at ICAD 2008.
- 12 Mar 2008 Status changed from in progress to completed according to ClinicalTrials.gov.